Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uridine and pravastatin for HIV-associated lipoatrophy after switch to lopinavir/ritonavir
ACTRN12608000307303Phase 4Completed
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of uridine, pravastatin and lopinavir + ritonavir in HAART-associated lipoatrophy (HAL) (4 arms), sponsored by St Vincent's Hospital Sydney. Primary endpoint: Change in limb fat mass at Week 28. Started Feb 2007; status: completed.
02
Drugs
uridinepravastatinlopinavir + ritonavir
03
Conditions
HAART-associated lipoatrophy (HAL)
Beyond the preview
Go deeper on ACTRN12608000307303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000307303.